| Literature DB >> 30646123 |
Cléa Melenotte1,2, Camélia Protopopescu3,4, Matthieu Million1,2, Sophie Edouard1,2, M Patrizia Carrieri1,4, Carole Eldin1,2, Emmanouil Angelakis1,2, Félix Djossou5, Nathalie Bardin1,6, Pierre-Edouard Fournier1,2, Jean-Louis Mège1,6, Didier Raoult1,2.
Abstract
Importance: Q fever remains widespread throughout the world; the disease is serious and causes outbreaks and deaths when complications are not detected. The diagnosis of Q fever requires the demonstration of the presence of Coxiella burnetii and the identification of an organic lesion. Objective: To describe the hitherto neglected clinical characteristics of Q fever and identifying risk factors for complications and death. Design, Setting, and Participants: This prospective cohort study conducted from January 1, 1991, through December 31, 2016, included patients treated at the French National Reference Center for Q fever with serologic findings positive for C burnetii and clinical data consistent with C burnetii infection. Clinical data were prospectively collected by telephone. Patients with unavailable clinical data or an unidentified infectious focus were excluded. Main Outcomes and Measures: Q fever complications and mortality.Entities:
Mesh:
Year: 2018 PMID: 30646123 PMCID: PMC6324270 DOI: 10.1001/jamanetworkopen.2018.1580
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure 1. Study Flowchart
Among the 2434 patients included in the study analysis, 1668 had only acute Q fever, 628 had only persistent focalized C burnetii infection, and 138 had an acute Q fever that evolved to a persistent C burnetii infection. NRC indicates National Reference Center.
Figure 2. Clinical Presentations of Coxiella burnetii Infection
Includes a total of 2434 patients with positive C burnetti serologic findings consistent with C burnetti infection.
Evolution to Persistent Coxiella burnetii Infection in 1806 Patients With Acute Q Fever
| Patient Characteristic | No. (%) of Patients | Univariate Analysis | Logistic Regression | ||||
|---|---|---|---|---|---|---|---|
| Acute Q Fever Without Persistent | Acute Q Fever Progressing to Persistent | Univariate | Multivariate | ||||
| OR (95% CI) | OR (95% CI) | ||||||
| Immunosuppression | |||||||
| No | 1608 (96.4) | 132 (95.7) | NA | 1 [Reference] | NA | NA | NA |
| Yes | 60 (3.6) | 6 (4.3) | .63 | 1.2 (0.5-2.9) | .65 | NR | NA |
| Valvulopathy | |||||||
| No | 1498 (89.8) | 53 (38.4) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 170 (10.2) | 85 (61.6) | <.001 | 14.1 (9.7-20.6) | <.001 | 9.8 (6.1-15.8) | <.001 |
| Sex | |||||||
| Male | 1115 (66.8) | 110 (79.7) | .002 | 1.9 (1.3-3.0) | .002 | 1.9 (1.1-3.1) | .01 |
| Female | 553 (33.2) | 28 (20.3) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| Age at baseline, median (IQR), y | 48 (37-59) | 55.5 (46-68) | <.001 | 1.03 (1.02-1.04) | <.001 | 1.01 (1.00-1.03) | .03 |
| Year category at baseline | |||||||
| Before 2009 | 186 (11.2) | 55 (39.9) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| 2009-2012 | 680 (40.8) | 32 (23.2) | NA | 4.6 (3.1-7.0) | <.001 | 3.2 (1.9-5.3) | <.001 |
| After 2012 | 802 (48.1) | 51 (37.0) | .03 | 0.7 (0.5-1.2) | .19 | 0.8 (0.5-1.4) | .42 |
| Pneumonia | |||||||
| No | 1211 (72.6) | 115 (83.3) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 457 (27.4) | 23 (16.7) | .005 | 0.5 (0.3-0.8) | .007 | 0.6 (0.3-1.0) | .07 |
| Lymphadenitis | |||||||
| No | 1616 (96.9) | 124 (89.9) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 52 (3.1) | 14 (10.1) | <.001 | 3.5 (1.9-6.5) | <.001 | 3.3 (1.6-7.1) | .002 |
| Thrombosis | |||||||
| No | 1657 (99.3) | 133 (96.4) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 11 (0.7) | 5 (3.6) | .005 | 5.7 (1.9-16.5) | .002 | 6.8 (1.9-24.8) | .004 |
| Acute endocarditis | |||||||
| No | 1636 (98.1) | 120 (87.0) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 32 (1.9) | 18 (13.0) | <.001 | 7.7 (4.2-14.1) | .001 | 3.8 (1.5-9.8) | .006 |
| IgG titer to phase I on first serologic analysis | |||||||
| ≤800 | 1476 (88.5) | 84 (60.9) | NA | 1 [Reference] | NA | NA | NA |
| >800 | 192 (11.5) | 54 (39.1) | <.001 | 4.9 (3.4-7.2) | <.001 | NR | NA |
| Maximum IgG titer to phase I | |||||||
| ≤800 | 1313 (78.8) | 48 (34.8) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| >800 | 354 (21.2) | 90 (65.2) | <.001 | 7.0 (4.8-10.1) | <.001 | 5.2 (3.3-8.1) | <.001 |
| IgG aCL antibody titer | |||||||
| ≤90 GPLU | 722 (77.4) | 59 (67.8) | NA | 1 [Reference] | NA | NA | NA |
| >90 GPLU | 211 (22.6) | 28 (32.2) | .048 | 1.6 (1.0-2.6) | .046 | NR | NA |
| Positive | |||||||
| No | 1481 (91.3) | 105 (77.8) | NA | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 142 (8.7) | 30 (22.2) | <.001 | 3.0 (1.9-4.6) | <.001 | 1.9 (1.0-3.4) | .03 |
Abbreviations: GPLU, IgG anti–phospholipid-binding units; IgG aCL, G-isotype anticardiolipin; IQR, interquartile range; NA, not applicable; NR, not retained in the model; OR, odds ratio; PCR, polymerase chain reaction.
Calculated using the 2-sided Fisher exact test or 2-sided t test.
Positive aCL Antibodies Associated With Clinical Complications of Coxiella burnetii Infection in 1328 Patients With Available IgG aCL Titers
| Acute Q Fever Manifestation | No. (%) of Patients | Univariate Analysis | Multivariate Logistic Regression | ||
|---|---|---|---|---|---|
| IgG aCL ≤22 GPLU (n = 830) | IgG aCL >22 GPLU (n = 498) | OR or IRR (95% CI) | |||
| Pneumonia (n = 319) | 236 (28.4) | 83 (16.7) | <.001 | 0.5 (0.4-0.6) | <.001 |
| Hepatitis (n = 503) | 217 (26.1) | 286 (57.4) | <.001 | 3.7 (2.9-4.7) | <.001 |
| Cholecystitis (n = 5) | 1 (0.1) | 4 (0.8) | .07 | 6.9 (0.7-62.8) | .09 |
| Hemophagocytic syndrome (n = 9) | 0 | 9 (1.8) | <.001 | NR | NR |
| Acute endocarditis (n = 42) | 13 (1.6) | 28 (5.6) | <.001 | 3.9 (2.0-7.5) | <.001 |
| Thrombosis (n = 21) | 10 (1.2) | 11 (2.2) | .18 | 2.1 (0.9-5.2) | .09 |
Abbreviations: aCL, anticardiolipin; GPLU, IgG anti–phospholipid-binding units; IRR, incidence rate ratio; NR, not retained in this model; OR, odds ratio.
Calculated using the 2-sided Fisher exact test or χ2 test.
All multivariate models are adjusted for sex, age, and year category at baseline (before 2009, 2009-2012, and after 2012).
Odds ratio calculated using multivariate logistic regression.
Incidence rate ratio calculated using multivariate Poisson regression.
Figure 3. Kaplan-Meier Survival Analysis
Includes patients with Coxiella burnetii infection. PEI indicates persistent endocarditis; PVI, persistent vascular infection.